| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
ORIGINAL RESEARCH |
From the Department of Obstetrics and Gynecology, New York University Medical Center, New York, New York; Department of Obstetrics and Gynecology, Algemene Kliniek St. - Jan, Brussels, Belgium; and Lilly Research Laboratories, Indianapolis, Indiana.
Address reprint requests to: Steven R. Goldstein, MD, New York University Medical Center, Department of Obstetrics and Gynecology, 530 First Avenue, New York, NY 10016; E-mail: steven.goldstein{at}med.nyu.edu
OBJECTIVE: To assess the effects of raloxifene therapy on the frequency of surgery for pelvic floor relaxation in postmenopausal women.
METHODS: This analysis used safety data through 3 years of treatment from three double-masked, placebo-controlled, randomized trials of raloxifene, which included 6926 postmenopausal women with uteri at entry. Studies 1 and 2 enrolled 969 nonosteoporotic, postmenopausal women who were assigned to 30, 60, or 150 mg per day raloxifene or placebo. Study 3 enrolled 5957 osteoporotic, postmenopausal women randomized to raloxifene 60 or 120 mg per day or placebo. Indications for any reported pelvic operations were identified, including procedures performed for pelvic organ prolapse or urinary incontinence.
RESULTS: A total of 34 (1.51%) women in the placebo group and 35 (0.75%) raloxifene-treated women underwent surgical procedures for pelvic floor relaxation. The odds ratio (and 95% confidence interval) for pelvic floor repair in women assigned to raloxifene was 0.50 (0.31, 0.81). Thus, raloxifene therapy was associated with a significantly reduced risk for pelvic floor surgery (P < .005).
CONCLUSION: Raloxifene does not increase pelvic floor relaxation. An apparent protective effect on pelvic floor function warrants further investigation.
This article has been cited by other articles:
|
|
 |
|
  L.M. Helvering, M.D. Adrian, A.G. Geiser, S.T. Estrem, T. Wei, S. Huang, P. Chen, E.R. Dow, J. N. Calley, J.A. Dodge, et al. Differential Effects of Estrogen and Raloxifene on Messenger RNA and Matrix Metalloproteinase 2 Activity in the Rat Uterus Biol Reprod, April 1, 2005; 72(4): 830 - 841. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Nygaard, C. Bradley, and D. Brandt Pelvic Organ Prolapse in Older Women: Prevalence and Risk Factors Obstet. Gynecol., September 1, 2004; 104(3): 489 - 497. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. R. Reid, R. Eastell, I. Fogelman, J. D. Adachi, A. Rosen, C. Netelenbos, N. B. Watts, E. Seeman, A. V. Ciaccia, and M. W. Draper A Comparison of the Effects of Raloxifene and Conjugated Equine Estrogen on Bone and Lipids in Healthy Postmenopausal Women Arch Intern Med, April 26, 2004; 164(8): 871 - 879. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. D. Slayden, K. Hettrich, R. S. Carroll, L. N. Otto, A. L. Clark, and R. M. Brenner Estrogen Enhances Cystatin C Expression in the Macaque Vagina J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 883 - 891. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. E. Waetjen, J. S. Brown, K. Modelska, T. Blackwell, E. Vittinghoff, and S. R. Cummings Effect of Raloxifene on Urinary Incontinence: A Randomized Controlled Trial Obstet. Gynecol., February 1, 2004; 103(2): 261 - 266. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. T. Chlebowski, N. Col, E. P. Winer, D. E. Collyar, S. R. Cummings, V. G. Vogel III, H. J. Burstein, A. Eisen, I. Lipkus, and D. G. Pfister American Society of Clinical Oncology Technology Assessment of Pharmacologic Interventions for Breast Cancer Risk Reduction Including Tamoxifen, Raloxifene, and Aromatase Inhibition J. Clin. Oncol., August 1, 2002; 20(15): 3328 - 3343. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
